Shares of Endo International PLC (NASDAQ:ENDP) traded down 2.9% during trading on Friday . The company traded as low as $17.30 and last traded at $17.37, with a volume of 1,916,143 shares changing hands. The stock had previously closed at $17.89.

A number of analysts recently commented on the company. Nomura reaffirmed a “buy” rating on shares of Endo International PLC in a research note on Saturday, April 2nd. Barclays PLC reaffirmed a “hold” rating on shares of Endo International PLC in a research note on Sunday, May 8th. JMP Securities reaffirmed a “buy” rating and set a $52.00 price objective (down previously from $56.00) on shares of Endo International PLC in a research note on Sunday, May 8th. Mizuho lowered Endo International PLC from a “neutral” rating to an “underperform” rating and decreased their price objective for the company from $42.00 to $13.00 in a research note on Tuesday, May 3rd. Finally, Zacks Investment Research lowered Endo International PLC from a “hold” rating to a “sell” rating in a research note on Tuesday, May 3rd. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating and ten have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $39.19.

The firm’s 50 day moving average price is $16.83 and its 200 day moving average price is $30.33. The firm’s market capitalization is $3.87 billion.

Endo International PLC (NASDAQ:ENDP) last issued its quarterly earnings results on Thursday, May 5th. The company reported $1.08 earnings per share for the quarter, beating analysts’ consensus estimates of $1.04 by $0.04. The business had revenue of $963.54 million for the quarter, compared to analysts’ expectations of $960.96 million. During the same quarter in the prior year, the firm posted $1.17 EPS. The business’s quarterly revenue was up 34.9% compared to the same quarter last year. Equities research analysts forecast that Endo International PLC will post $4.55 earnings per share for the current year.

In other Endo International PLC news, Director Arthur J. Higgins purchased 11,000 shares of the stock in a transaction dated Tuesday, May 10th. The shares were acquired at an average price of $15.42 per share, for a total transaction of $169,620.00. Following the completion of the acquisition, the director now owns 45,623 shares of the company’s stock, valued at approximately $703,506.66. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Paul Campanelli purchased 13,000 shares of the stock in a transaction dated Tuesday, May 10th. The shares were acquired at an average price of $15.53 per share, for a total transaction of $201,890.00. Following the acquisition, the insider now directly owns 201,069 shares of the company’s stock, valued at approximately $3,122,601.57. The disclosure for this purchase can be found here.

A number of hedge funds and institutional investors have recently modified their holdings of the stock. Advantus Capital Management Inc increased its position in shares of Endo International PLC by 2.4% in the fourth quarter. Advantus Capital Management Inc now owns 19,971 shares of the company’s stock worth $1,223,000 after buying an additional 476 shares during the period. BNP Paribas Arbitrage SA increased its position in shares of Endo International PLC by 4.7% in the fourth quarter. BNP Paribas Arbitrage SA now owns 273,393 shares of the company’s stock worth $16,737,000 after buying an additional 12,234 shares during the period. Finally, Cibc World Markets Corp purchased a new position in shares of Endo International PLC during the fourth quarter worth approximately $47,081,000.

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.